Impact of Cognitive & Metacognitive Performance on Knowledge Learning When Conducting Therapeutic Education Programs

NCT ID: NCT04590300

Last Updated: 2024-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-06

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with schizophrenia and bipolar disorder display alterations in cognition and metacognition. These alterations may have an impact on learning during therapeutic education programs.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient Therapeutic Education (FTE) is defined as a practice to help patients to acquire or maintain the skills needed to best manage their lives with a chronic disease. FTE includes organized awareness, information, learning and psychological and social assistance about the disease, prescribed treatments, various treatments offered, as well as information on organization of the global health system, and health behaviours. Performed by health professionals trained in this practice, FTE is intended to help patients and their close relatives and to understand their pathology, their treatments, collaborate with health care teams, and maintain or improve their quality of life. It aims to produce a complementary therapeutic effect of other health care interventions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Schizophrenia

1 questionnaire at the beginning of the study, before FTE program

1 questionnaire at the end of FTE

Group Type OTHER

QUESTIONNAIRES

Intervention Type OTHER

1 questionnaire at the beginning of the study, before FTE program

1 questionnaire at the end of FTE

Bipolar disorder

1 questionnaire at the beginning of the study, before FTE program

1 questionnaire at the end of FTE

Group Type OTHER

QUESTIONNAIRES

Intervention Type OTHER

1 questionnaire at the beginning of the study, before FTE program

1 questionnaire at the end of FTE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QUESTIONNAIRES

1 questionnaire at the beginning of the study, before FTE program

1 questionnaire at the end of FTE

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Consent to participate in the study,
* Suffering from a chronic condition for which an therapeutic patient education (TEP) program is proposed.
* Mastering the French language.
* Be a beneficiary of health insurance

Exclusion Criteria

* Poor understanding of instructions that make it impossible to consent or assess
* Neurodegenerative disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Charles Perrens, Bordeaux

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clelia QUILES, MD

Role: PRINCIPAL_INVESTIGATOR

CH Charles Perrens

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier CHARLES PERRENS

Bordeaux, Nouvelle-Aquitaine, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Xia J, Merinder LB, Belgamwar MR. Psychoeducation for schizophrenia. Cochrane Database Syst Rev. 2011 Jun 15;2011(6):CD002831. doi: 10.1002/14651858.CD002831.pub2.

Reference Type BACKGROUND
PMID: 21678337 (View on PubMed)

Soo SA, Zhang ZW, Khong SJ, Low JEW, Thambyrajah VS, Alhabsyi SHBT, Chew QH, Sum MY, Sengupta S, Vieta E, McIntyre RS, Sim K. Randomized Controlled Trials of Psychoeducation Modalities in the Management of Bipolar Disorder: A Systematic Review. J Clin Psychiatry. 2018 May/Jun;79(3):17r11750. doi: 10.4088/JCP.17r11750.

Reference Type BACKGROUND
PMID: 29727072 (View on PubMed)

Flavell J.H. Metacognition and cognitive monitoring. A new area of cognitive-developmental inquiry. Am Psychol. 1979; 34(10):906-11

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A00980-39

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.